Protocol Ledger

NCT04353817 · Phase III · COMPLETED

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Interventional Phase III clinical trial protocol NCT04353817 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-19 Enrollment: 121 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04353817
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04353817
Protocol FieldVerified Registry Value
NCT IdentifierNCT04353817
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment121 participants (ACTUAL)
Registered Start Date2020-06-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04353817
Hospital Research SiteLocationSite Profile
Queensland Children's HospitalSouth Brisbane, AustraliaOpen Hospital Dossier ->
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
The Hospital for Sick ChildrenToronto, CanadaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI